Compare MCHX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | RVPH |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | 163 | 14 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 29.2M |
| IPO Year | 2003 | N/A |
| Metric | MCHX | RVPH |
|---|---|---|
| Price | $1.41 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $66.67 |
| AVG Volume (30 Days) | 11.1K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,291,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.17 |
| 52 Week High | $2.30 | $3.11 |
| Indicator | MCHX | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 75.19 |
| Support Level | $1.35 | $0.32 |
| Resistance Level | $1.76 | N/A |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.28 |
| Stochastic Oscillator | 31.25 | 76.53 |
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.